BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
See today's BioWorld
Home
» Clinic Roundup
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Clinic Roundup
Nov. 25, 2013
No Comments
• Threshold Pharmaceuticals Inc., of South San Francisco, reported early data from a Phase I trial of TH-302 in combination with Avastin (bevacizumab, Roche AG) for recurrent glioblastoma.
BioWorld